Skip to content

The impact of enhanced external counterpulsation therapy on the prognosis of heart failure patients with preserved ejection fraction

The impact of enhanced external counterpulsation therapy on the prognosis of heart failure patients with preserved ejection fraction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083703
Enrollment
Unknown
Registered
2024-04-30
Start date
2024-05-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction

Interventions

Exposure group (Drug and EECP treatment ):NA
Control group (Drug treatment):NA

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age between 20 and 80 years old; (2) Patients with CHD and HFpEF(LVEF =50% and cardiac diastolic dysfunction), and CAG result shows moderate to severe stenosis; (3) Cardiac function: II~III(NYHA); (4) Exercise ability: exercise time can reach over 3 minutes, and is only limited by heart failure symptoms; (5) Clinical symptoms are stable; (6) Informed consent has been signed before participating in the study. Control group Select HFpEF patients with concomitant coronary heart disease who meet the inclusion criteria during the same period.

Exclusion criteria

Exclusion criteria: (1) Moderate to severe peripheral edema; (2) ACS diagnosed within 2 weeks before participating in the study; (3) Patients have been performed CABG or PCI within 1 week before participating in the study; (4) Contraindications of EECP : (1) severe arrhythmias interfering with EECP device triggering; (2) various bleeding disorders or bleeding tendencies; (3) active thrombophlebitis; (4) decompensated heart failure (central venous pressure > 12mmHg with pulmonary edema); (5)Severe pulmonary hypertension (mean pulmonary arterial pressure > 50mmHg) ;(6) severe aortic insufficiency;(7) deep venous thrombosis of the lower extremity;(8) aortic aneurysm requiring surgical intervention; (9) pregnant women; (10) recent cardiac catheterization (within 2 weeks). Others include arrhythmia, cardiomegaly, hypertrophic cardiomyopathy, and uncontrolled hypertension (SBP=180 mmHg, DBP=110 mmHg); (5) Cognitive and psychiatric disorders affecting clinical data collection

Design outcomes

Primary

MeasureTime frame
Six-minute walking distance;Readmission Rate;

Secondary

MeasureTime frame
Cardiac function;NT-proBNP;Cardiovascular events;

Countries

China

Contacts

Public ContactLiu Chen

The First Affiliated Hospital of Sun Yat-sen University

chenliu81@hotmail.com+86 150 1327 0269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026